Last reviewed · How we verify
NCT06740786
Efficacy and Safety of Dapagliflozin in Preventing Atrial Fibrillation Recurrence After Catheter Ablation
NA trial testing Dapagliflozin Treatment Group in Atrial Fibrillation (AF) in 250 participants. Not yet recruiting.
1 May 2026
Quick facts
| Lead sponsor | Xu Liu |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 250 |
| Start date | 10 December 2024 |
| Primary completion | 1 May 2026 |
| Estimated completion | 1 May 2026 |
Drugs / interventions tested
- Dapagliflozin Treatment Group — full drug profile →
Conditions studied
- Atrial Fibrillation (AF) — all drugs for Atrial Fibrillation (AF) →
Sponsor
Xu Liu — full company profile →
Who can join
18 and older, any sex, with Atrial Fibrillation (AF). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Atrial fibrillation (AF) is a common arrhythmia, particularly prevalent in the elderly population. Catheter ablation is a common treatment for AF, but post-ablation recurrence of arrhythmias remains a significant clinical challenge. Dapagliflozin, an SGLT2 inhibitor primarily used for the treatment of type 2 diabetes, has shown potential in the field of cardiology, particularly for treating heart failure patients. Some studies suggest that dapagliflozin may reduce cardiac workload, improve heart function, and could even help in the management of atrial fibrillation. Therefore, this study aims to explore whether dapagliflozin can reduce the recurrence of arrhythmias following atrial fibrillation catheter ablation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06740786
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Atrial Fibrillation (AF)
Currently open trials in the same condition.
- NCT07298473 — Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sp · NA · recruiting
- NCT07442175 — Blood Pressure Monitor (TH-75) Atrial Fibrillation Detection Function Clinical Trial · recruiting
- NCT07389434 — Feasibility, Safety, Cost-effectiveness, and Environmental Impact of Reprocessed Ablation Catheters in PVI · NA · recruiting
- NCT07250529 — Left Bundle Branch Pacing vs Right Ventricular Pacing on AHRE Burden in Patients With Preserved LVEF · NA · recruiting
- NCT07358611 — Non-invasive Mapping-Guided Atrial Fibrillation Ablation · NA · recruiting
Other Xu Liu trials
Trials by the same sponsor.
- NCT06947590 — Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy · NA · active not recruiting
- NCT06892808 — Impact of Periodontal Therapy on AF Recurrence Post-Ablation in High-Inflammatory Burden Patients · NA · active not recruiting
- NCT06729866 — EGM Guided PFA for PerAF · NA · active not recruiting
- NCT05883722 — Adjunctive Right Atrial Ablation for Persistent Atrial Fibrillation · NA · unknown
- NCT07153718 — Optimal Ablation Strategies for Persistent AF With HF · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06740786 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xu Liu
- Last refreshed: 18 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06740786.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing